Clinical Trials on PSA Level Greater Than 0.03 in Poland

Total 2 results

OHSU Knight Cancer Institute
United States Department of Defense; Oregon Health and Science University

Completed

Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide

Castration-Resistant Prostate Carcinoma | Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | PSA Progression | Castration Levels of Testosterone

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | PSA Progression | Stage IV Prostate Adenocarcinoma AJCC v7 | Castration Levels of Testosterone

United States

3

Subscribe